Agenus shared a post on LinkedIn:
“Agenus to Host October Stakeholder Briefing: Showcasing BOT/BAL Global Momentum and Post-ESMO Insights
Join us Tuesday, October 21 at 4:00 p.m. ET for a webcast moderated by Dr. Garo Armen, Agenus Founder, Chairman & CEO.
The session will feature:
Dr. Michael Gordon (HonorHealth Research Institute) sharing results from his ESMO 2025 presentation of >400 patients treated with BOT/BAL across multiple refractory tumors.
Professor Alexander Eggermont, renowned immuno-oncologist, discussing France’s AAC access program and the inclusion of BOT/BAL for MSS mCRC.
A live Q&A will follow.
You Can Also Read: BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing
